PT-141 Research Guide: Identity, Literature, Analysis and Documentation
Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.
PT-141 is the same seven-residue lactam ring as Melanotan II with one difference at the very end: a free carboxylic acid where Melanotan II has an amide. That single change adds about 1 dalton, makes the molecule more acidic, and is the whole basis for telling the two apart on a certificate. The sequence is also the active substance of an approved medicine, bremelanotide. This page collects the identity data, the research areas the literature covers, the analytical points, and the report on file for StarBio’s lot.
Identity
| Name | PT-141 (bremelanotide) |
|---|---|
| Type | Synthetic cyclic heptapeptide, lactam-bridged, free C-terminal acid |
| CAS number | 189691-06-3 |
| Molecular weight | 1025.18 g/mol |
| Formula | C50H68N14O10 |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Length | 7 (cyclic heptapeptide) |
Origin and history
PT-141 was developed by Palatin Technologies in the early 2000s from Melanotan II, of which it is the deamidated counterpart. After clinical trials it was approved in the United States in 2019 under the name bremelanotide. The literature on file is therefore almost entirely clinical and concerns that medicine. The material StarBio supplies is a synthetic research chemical of the same sequence, sold for laboratory use only. It is not the medicine, and nothing on this page describes a use of it.
What the literature covers
The references on file for this compound span several research areas. They are listed here as areas of study, not as results.
- Early development. Two papers from 2003 and 2004 describing PT-141 as a melanocortin agonist in development [2, 6] and a 2006 clinical study [8].
- The approved medicine. The 2019 approval summary [4], a 2023 evaluation [7] and a 2022 paper on its neurobiology [9].
- Clinical reviews. Reviews from 2021 and 2022 that survey the field in which the medicine is used [1, 3, 10, 11].
- The melanocortin system. A 2023 review in Nature Reviews Endocrinology of the central melanocortin system as a research target [5].
None of these papers describes research-grade material or any use of it.
Analytical notes
The certificate has to distinguish PT-141 from Melanotan II. The monoisotopic protonated masses are 1025.5 for PT-141 and 1024.5 for Melanotan II, a gap of one dalton that a low-resolution spectrum can confuse with an isotope peak. The reliable evidence is accurate mass together with retention time: the free acid makes PT-141 more polar at neutral pH, so the two do not co-elute.
As in Melanotan II, ring closure removes one water, so uncyclised linear material appears at +18 Da and is the characteristic synthesis impurity. The sequence contains tryptophan, which absorbs at 280 nm and is sensitive to light and oxidation, and a D-phenylalanine whose L-form impurity has the same mass and shows only as a separate peak. The doubly protonated ion sits at 513.3.
Storage and stability
- Lyophilized powder
- Store at -20 °C
- Protect from light
- Avoid repeated freeze-thaw cycles
- In solution: 2-8 °C, short term
Documentation for StarBio lots
Every StarBio lot is analysed by an independent laboratory. The table lists the report on file for this compound.
| Variant | Laboratory / report | HPLC purity | Labelled / measured | Tested | |
|---|---|---|---|---|---|
| PT-141 10 mg | Medutest WWB-P41-9870 | 99.70% | 10 mg | Feb 16, 2026 | report |
Current certificates are in the COA Library; the verify-lot form connects an order to its batch record.
References
- Medical Treatment of Female Sexual Dysfunction. The Urologic clinics of North America, 2022, PMID 35428435.
- PT-141 Palatin. Current opinion in investigational drugs (London, England : 2000), 2004, PMID 15134289.
- Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment. Journal of midwifery & women's health, 2021, PMID 34510696.
- Bremelanotide: First Approval. Drugs, 2019, PMID 31429064.
- Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology, 2023, PMID 37365323.
- PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 2003, PMID 12851303.
- An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023, PMID 36242769.
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The journal of sexual medicine, 2006, PMID 16839319.
- The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022, PMID 33455598.
- Pharmacotherapy for Sexual Dysfunction in Women. Current psychiatry reports, 2022, PMID 35102537.
- Pharmacologic therapeutic options for sexual dysfunction. Current opinion in obstetrics & gynecology, 2022, PMID 36036468.
Product page: PT-141. Related guides: Melanotan II research guide, Melanotan I research guide, what 99% purity means, storing lyophilized peptides.
For laboratory research use only. Not for human or veterinary use.
Compared with related compounds: Melanotan I vs Melanotan II vs PT-141.
Questions about PT-141
What is PT-141?
PT-141 is a cyclic melanocortin receptor agonist peptide: 7 residues (cyclic heptapeptide), molecular weight 1025.18 g/mol, CAS number 189691-06-3. It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.
Is PT-141 the same as Bremelanotide?
PT-141 is also listed as Bremelanotide. On a certificate or vial label, the CAS number (189691-06-3) and the sequence identify the material regardless of which name is used.
What are the CAS number, formula and molecular weight of PT-141?
PT-141 has CAS number 189691-06-3, molecular formula C50H68N14O10 and molecular weight 1025.18 g/mol. Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Identity of each StarBio batch is confirmed by mass spectrometry on the laboratory report.
Is StarBio's PT-141 independently tested?
Yes. The current PT-141 batch was tested by Medutest (Medutest report WWB-P41-9870): 99.70% purity by HPLC, tested Feb 16, 2026. The report is on file in the COA library (report page).
How should PT-141 be stored?
Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.
Where can I buy PT-141 for laboratory research?
StarBio sells PT-141 as 10 mg at $29.99, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.
New reports and guides, by email
A short note when a new laboratory report is published, when a compound returns to stock, and when a new guide goes up. Nothing else. Leave whenever you like.
For laboratory research use only. No dosing or protocol content is ever sent.

